Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism

被引:57
作者
Benowitz, NL
Jacob, P
机构
[1] Univ Calif San Francisco, San Francisco Gen Hosp, Med Ctr,Med Serv, Div Clin Pharmacol & Expt Therapeut, San Francisco, CA USA
[2] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[3] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA
关键词
D O I
10.1067/mcp.2000.107086
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: To examine the effects of cigarette smoking on the disposition kinetics of nicotine and cotinine, to determine the effects of cigarette smoking on pathways of nicotine and cotinine metabolism, and to test the hypothesis that carbon monoxide inhibits the metabolism of nicotine. Study design: Twelve cigarette smokers were studied in three treatment conditions, each lasting 7 days, during which they smoked cigarettes, breathed carbon monoxide to achieve carboxyhemoglobin levels similar to cigarette smoking, or breathed air. In each treatment condition, subjects received a combined infusion of deuterium-labeled nicotine (d(2)) and cotinine (d(4)), with measurement of disposition kinetics and urine metabolite profile. Results: Cigarette smoking significantly inhibited the metabolism of nicotine but had no effect on cotinine metabolism. Cigarette smoking markedly induced the O-glucuronidation of trans-3'-hydroxycotinine but had no effect on the N-glucuronidation of nicotine or cotinine, Carbon monoxide had no effect on nicotine or cotinine kinetics or metabolic profile. Conclusions: This study confirms previous observations that cigarette smoking inhibits nicotine metabolism but disproves the hypothesis that this effect is due to carbon monoxide, Induction of glucuronidation must be considered in understanding the effects of cigarette smoking on drug metabolism.
引用
收藏
页码:653 / 659
页数:7
相关论文
共 20 条
[11]   SELECTIVE-INHIBITION OF MAJOR-DRUG METABOLIZING CYTOCHROME-P450 ISOZYMES IN HUMAN LIVER-MICROSOMES BY CARBON-MONOXIDE [J].
LEEMANN, T ;
BONNABRY, P ;
DAYER, P .
LIFE SCIENCES, 1994, 54 (14) :951-956
[12]  
Messina ES, 1997, J PHARMACOL EXP THER, V282, P1608
[13]  
MONTGOMERY MR, 1971, J PHARMACOL EXP THER, V179, P465
[14]  
Nakajima M, 1996, J PHARMACOL EXP THER, V277, P1010
[15]  
Nakajima M, 1996, DRUG METAB DISPOS, V24, P1212
[16]   DISPOSITION OF OXAZEPAM IN RELATION TO AGE, SEX, AND CIGARETTE-SMOKING [J].
OCHS, HR ;
GREENBLATT, DJ ;
OTTEN, H .
KLINISCHE WOCHENSCHRIFT, 1981, 59 (16) :899-903
[17]   NICOTYRINE INHIBITS INVIVO METABOLISM OF NICOTINE WITHOUT INCREASING ITS TOXICITY [J].
STALHANDSKE, T ;
SLANINA, P .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1982, 65 (03) :366-372
[18]  
WALLE T, 1987, J PHARMACOL EXP THER, V241, P928
[19]   Drug interactions with tobacco smoking - An update [J].
Zevin, S ;
Benowitz, NL .
CLINICAL PHARMACOKINETICS, 1999, 36 (06) :425-438
[20]   Cotinine effects on nicotine metabolism [J].
Zevin, S ;
Jacob, P ;
Benowitz, N .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (06) :649-654